Scarred Lung. An Update on Radiation-Induced Pulmonary Fibrosis

Natalia Jarzebska1,2, Ekaterina S. Karetnikova3, Alexander G. Markov3, Michael Kasper4, Roman N. Rodionov2 and Peter M. Spieth1*

1 Department of Anesthesiology and Critical Care Medicine, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany, 2 Division of Angiology, Department of Internal Medicine III, University Center for Vascular Medicine, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany, 3 Department of General Physiology, Saint-Petersburg State University, Saint Petersburg, Russia, 4 Institute of Anatomy, Technische Universität Dresden, Dresden, Germany

Radiation-induced pulmonary fibrosis is a common severe long-time complication of radiation therapy for tumors of the thorax. Current therapeutic options used in the clinic include only supportive management strategies, such as anti-inflammatory treatment using steroids, their efficacy, however, is far from being satisfactory. Recent studies have demonstrated that the development of lung fibrosis is a dynamic and complex process, involving the release of reactive oxygen species, activation of Toll-like receptors, recruitment of inflammatory cells, excessive production of nitric oxide and production of collagen by activated myofibroblasts. In this review we summarized the current state of knowledge on the pathophysiological processes leading to the development of lung fibrosis and we also discussed the possible treatment options.

Keywords: radiation, pulmonary fibrosis, macromolecular damage, nitric oxide, dimethylarginine dimethylaminohydrolase

INTRODUCTION

Radiation therapy is an integral part of the treatment of various malignant neoplasms (1), including tumors of the thorax (2–4). Radiation induced pulmonary fibrosis is a common complication of this therapy affecting 5–50% of patients, which significantly limits available treatment options even after successful eradication of the tumor itself (5). Radiation-induced lung injury can be divided into two distinct forms: (1) classical radiation pneumonia, which is restricted to the irradiated area and leads to fibrosis and (2) sporadic radiation pneumonia, affecting much broader area than the tissue which was subjected to irradiation and resulting in bilateral lymphocytic alveolitis, mediated by various immunological processes (6, 7). Currently, corticosteroids, azathioprine, and cyclosporin A are used as first line treatment for post-radiation pneumonitis (8, 9). Ambroxol and angiotensin-converting enzyme inhibitors are suggested as additional drugs to prevent or attenuate the extent of pneumonitis (10, 11). Lung fibrosis, however, is an end stage of radiation-induced pneumonitis and in most of the cases it is resistant to all currently known pharmacological interventions. Previously only symptomatic treatment with antitussive agents, oxygen therapy, and mechanical ventilation was available (9). More recently, it was shown that nintedanib, a multiple tyrosine kinase inhibitor, and pirfenidone, a TGF-β inhibitor, exhibit anti-inflammatory and anti-fibrotic effects in experimental murine irradiation models (12, 13) and these drugs are now in clinical use for treatment of pulmonary fibrosis (13, 14).
The aim of this review is to summarize and analyse the currently available data on the pathophysiological mechanisms leading to lung fibrosis. Hopefully it will allow identifying promising directions for further research, which will lead to the development of effective preventive and/or treatment approaches to tackle post-radiation pulmonary fibrosis.

CLINICAL PERSPECTIVE

The lung parenchyma is one of the most radiation-sensitive tissues with the alveolar-capillary unit being the most vulnerable part of the lung (15). The likelihood of developing side effects of radiation therapy, like difficulty swallowing, shortness of breath, breast or nipple soreness and shoulder stiffness depends on many factors like patient-related variables, the nature of the tumor itself and the parameters of radiation therapy (16–18). Specifically, it has been demonstrated that age above 65 years, smoking, presence of co-morbidities and poor pulmonary function tests (decreased forced expiratory volume and poor diffusing capacity of the lungs for carbon monoxide) have been associated with increased incidence of radiation pneumonitis (19, 20). Additionally, radiation therapy administered for mid and lower lobe lung tumors, breast cancer with tangential fields and esophageal cancer are also correlated with significantly increased incidence of radiation pneumonitis (20). Other risk factors include more than 30% of the planned target volume receiving 20 Gy or more, and the use of certain medications like bleomycin, cyclophosphamide, vincristine, taxanes, doxorubicin, daclomycin, mitomycin, gemcitabine, erlotinib and bevacizumab (21–25). There are also certain molecular markers reported, which could be used to improve individualized treatment. For example, patients with elevated post treatment serum TGF-β1 (transforming growth factor beta 1) levels above baseline exhibit a significantly higher risk of radiation induced lung injury (26, 27). Furthermore, persistently elevated IL1a (interleukin 1 alpha) and IL6 (interleukin 6), ICAM 1 (intercellular adhesion molecule 1), SP-A (surfactant protein A) and SP-D (surfactant protein D) serum levels are predictive for the development of radiation pneumonitis (28–30). Furthermore, certain ATM (ataxia telangiectasia mutated) gene polymorphisms have been associated with increased risk of radiation pneumonitis (31). Finally, there are also studies showing that the risk of severe radiation pneumonitis is increased in patients with pre-existing idiopathic pulmonary fibrosis (IPF) (32–34). Nonetheless, there are no formal guidelines limiting the eligibility of IPF patients for thoracic radiotherapy, even though according to the recommendations of the European Organization for Research and Treatment of Cancer radiotherapy for lung cancer should be avoided in IPF patients (35). The decision of whether or not to treat these vulnerable patients with irradiation of the thorax should be made after a careful evaluation of a multidisciplinary team taking into account a comprehensive risk assessment. Clearly more research is needed to establish the safest treatment options. The group of Yoshitake and colleagues investigated the side effects of thoracic stereotactic body radiotherapy (SBRT) in patients with interstitial lung changes (ILC) and found that the risk of radiation pneumonitis grade 2 or more was increased in patients with subclinical ILC (36). Even though the topic still requires more research, dose limits for SBRT in patients with pre-existing ILC are recommended (37). There is an increasing body of evidence suggesting that proton beam therapy could be a safer option in patients with IPF than conventional radiotherapy or SBRT (38–41). However, prospective, multicentre studies with large number of patients enrolled are still needed. Nintedanib is a relatively new drug that can be used to slow the progression of IPF. It is a tyrosine kinase inhibitor affecting tyrosine phosphorylation on platelet-derived growth factor, vascular endothelial growth factor and fibroblast growth factor leading to suppression of inflammation, angiogenesis and fibroblast activation (42). The drug has been shown to prevent/retard acute exacerbations in patients with IPF (43, 44), however it was not effective in alleviating bleomycin-induced pulmonary fibrosis in an animal model (45).

Apart from causing pneumonitis and pulmonary fibrosis, radiotherapy is also thought to contribute to activation of cancer-associated fibroblasts (CAF), at least in some conditions. CAFs are a heterogeneous group of stromal cells inside a tumor, which differ epigenetically and phenotypically from normal fibroblasts. The major cellular origin of CAFs are normal fibroblasts that are transformed by the tumor microenvironment, however, smooth muscle cells, pericytes, adipocytes, mesenchymal stem cells and endothelial cells are also demonstrated to be the source of CAFs (46, 47). Those cells modulate the composition of the extracellular matrix through secretion of growth factors and cytokines which lead to regulation of tumor proliferation, invasion and the potential for metastasis. Interestingly, there are also studies demonstrating that CAFs can slow down tumor progression by formation of a physical barrier which limits tumor growth and the possibility to migrate (48). Radiotherapy affects the proliferation of CAFs at the genetic level, but does not limit the ability of these cells to sustain a microenvironment which supports tumor growth (49). The influence of radiotherapy on the CAFs is a matter of ongoing investigations. On one hand, there is data supporting the idea that irradiation can modify the CAFs leading to abrogation of tumor promoting ability (50), however, there are also studies showing that irradiated fibroblasts can induce epithelial-to-mesenchymal transition (EMT) in cancer cells and promote invasiveness through elevation of TGF-β levels (51, 52). In line with this data, the group of Ohuchida et al. showed that irradiated CAFs increase the invasiveness in pancreatic cancer cells (53). In another study it was demonstrated in the same type of cancer that CAFs after irradiation induce EMT and invasiveness by activation of the P38 pathway (54).

CASCADE OF PATHOPHYSIOLOGICAL PROCESSES LEADING TO LUNG FIBROSIS

Primary and Secondary Damage to Macromolecules

Exposure to radiation causes both direct and indirect macromolecular damage and also triggers the generation of...
of proinflammatory cytokines and pyroptosis in lung tissue. IL-1β also plays an important role in initiation of the acute inflammatory responses by binding to its ubiquitously expressed receptor (IL-1R-1) and stimulation of the production of TGF-β, pro-IL-1β, TNF-α, and IL-6. Together these cytokines promote the recruitment and activation of innate immune cells, as well as trigger and enhance cascades of aseptic inflammation in the damaged part of the lung (18, 71).

**P2X Purinoreceptor 7**

The NLRP3 inflammasome might be also involved in the pathogenesis of radiation-induced fibrosis by activating purinergic P2X and P2Y receptors (purinergic signaling). Purinergic signaling is involved in ionizing radiation-induced biological effects (75). An important protein in these pathways is the ATP-stimulated P2X purinoreceptor 7 (P2X7R), selectively present in alveolar macrophages and in alveolar epithelial type I cells in lungs and known to regulate the activation of the NLRP3 inflammasome. A rapid increase in the extracellular ATP concentration, for example after damage of a tissue or after cell death, causes an endogenous signal of danger and activates the NLRP3 inflammasome by binding of ATP to P2X7R which functions as ligand-controlled ion channel (76). The effect of ATP may be transmitted by P2X7R, which causes the formation of pannexin-1 pores. Their opening leads to a fast outflow of K+-ions from the cytosol (77). The decrease in the cytoplasmic K+ concentration causes assembly and activation of the inflammasome leading to an auto- catalytic cleavage of the inactive procaspase-1 to its active form. The inflammasome transmitted caspase-1-dependent proteolytic cleavage of inactive proforms of cytokines of the IL-1-family (pro-IL-1β, pro-IL-18) results in biological active forms, which are released from cells as a part of the inflammatory reaction. Further, the involvement of the connexin43 hemichannel in the ATP release downstream of the P2X7R in response to irradiation has to be taken into account (78). An upregulation of connexin43 in alveolar epithelial cells of rats with radiation-induced pulmonary fibrosis has been described earlier (79). Furthermore, P2X7R knockout mice exhibited dramatically reduced lung inflammation and fibrosis, underlining the important role of P2X7R in fibrotic diseases (80).

**Inducible Nitric Oxide Synthase (iNOS), Asymmetric Dimethylarginine (ADMA) and Dimethylarginine Dimethylaminohydrolase (DDAH)**

IL-1β, TNF-α, and other cytokines activate iNOS, which starts to produce large quantities of NO. When nitric oxide is produced, it can bind to O2− with the formation of peroxynitrite (ONOO−) causing secondary damage to macromolecules (DNA, proteins, glucosaminoglycan hyaluronan, etc.) (81). The importance of peroxynitrite in lung fibrosis development has been demonstrated in animal studies where it was shown that iNOS knockout mice had significantly less fibrotic changes in the lungs compared to wild-type mice after bleomycin treatment (81–83). The activity of iNOS in vivo is regulated by asymmetric dimethylarginine (ADMA), its endogenous inhibitor. It has been
shown that at concentrations exceeding 10μM ADMA not only decreases NO production by iNOS but also uncouples it with the production of O$_3^-$ (84). It was speculated that the addition of ADMA to already fully active iNOS cannot reduce the damage to the lung tissue mediated by NO, but paradoxically can lead to further exacerbation of the damage due to the peroxynitrite formation. This assumption was confirmed by Wells and colleagues in in vitro and in vivo studies (84). They showed that ADMA elevates collagen production in primary mouse lung fibroblasts and that ADMA infusion via osmotic minipumps for 2 weeks caused collagen deposition in mice lungs (85). In the same manuscript the authors proposed an interesting pathway of pro-fibrotic ADMA activity where ADMA increases arginase activity leading to elevated levels of ornithine and urea; ornithine is a precursor of proline, an amino acid essential for collagen synthesis (85). In line with these observations, other study demonstrated that 21 days after bleomycin injury there was no difference in the fibrotic response in mice supplemented with ADMA and those given placebo (83). Concentration of ADMA is regulated by the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme which cleavages ADMA (86, 87). DDAH expression and activity increase in course of lung fibrosis development, through TGF-β and IL-6 which increase mRNA levels of DDAH2 (one of two DDAH isoforms) (83); and through IL-1β which enhances DDAH activity and rises its intracellular concentrations (88). Increased DDAH expression and activity in turn reduces ADMA concentration in lung tissue, which results in greater amounts of NO produced by iNOS, contributing to further damage of lung tissue.

**Sources of Fibroblasts:**

**Epithelial-Mesenchymal Transition (EMT), Endothelial-Mesenchymal Transition (EndMT) and Recruitment of Fibrocytes and Myofibroblasts**

Increased concentrations of TGF-β1 in course of development of lung fibrosis induce EMT (epithelial-mesenchymal transition) of alveolar epithelial cells type II (AET II cells) (89) and EndMT (endothelial-mesenchymal transition) of microvascular endothelial cells (90). During EMT and EndMT, the polarized epithelial and endothelial cells loose their polarity and specific markers such as E- or VE-cadherin, tight junction proteins etc., increase expression of mesenchymal markers (vimentin, collagens I and III, α-SMA etc), move to the interstitium and gain phenotype like mesenchymal cells (89). A convincing proof of EMT in vivo was demonstrated in lineage-tracing studies (91–93) where mice with selective expression of β-galactosidase (β-gal) only in lung epithelial cells were used. After induction of lung fibrosis by TGF-β1 (92), thorax irradiation (91) or by bleomycin treatment (93) the authors reported the appearance of expression of different mesenchymal markers (α-SMA, vimentin, S100A4) in β-gal-positive cells and the co-expression of mesenchymal markers and pro-surfactant C (a marker of AET II cells) (91–94). There is a controversy about the contribution of epithelial cells to myofibroblast population and to the physiological role of EMT in vivo (95, 96). Moreover, recent findings suggest that AET II cells undergoing EMT promote a pro-fibrotic microenvironment through paracrine signaling activating local fibroblasts (97). An EMT of AET I cells is unknown. The various cytokines produced during aseptic inflammation also promote the recruitment of fibrocytes from the peripheral blood and their differentiation into fibroblasts in the lung tissue, where they produce extracellular matrix (93, 98). The last step in the development of radiation-induced pulmonary fibrosis is the formation of myofibroblasts from fibroblasts (99). The cellular source of myofibroblasts has been a subject of debate in recent years. It was suggested that the myofibroblasts pool is heterogeneous and derives from multiple sources, such as resident fibroblasts, circulating fibroblasts, perivascular mesenchymal cells, and alveolar epithelial cells (95, 100–102). However, recent studies using genetic lineage tracing identified the resident lipid-droplet-containing interstitial fibroblasts, as a precursor cell for the myofibroblast, at least in the bleomycin model of lung fibrosis in mice (103). Regardless of the source, the differentiation of fibroblast into myofibroblasts is driven by TGF-β1 (103). Upon activation these cells produce excessive amounts of extracellular matrix (ECM) (fibronectin, collagen etc), which causes contraction of the lung tissue (104, 105) and increase the thickness of the alveolar-capillary membrane together leading to irreversible compromised diffusing capacity of the lung (106) and restrictive ventilatory insufficiency.

The various processes leading to irradiation-induced lung fibrosis are summarized in Figure 1.

![Figure 1](image-url)
RESEARCH TARGETS REGARDING LUNG FIBROSIS PREVENTION AND TREATMENT

Minimizing Protein Damage
Since the primary and secondary damage to macromolecules is the starting point for the development of all pathophysiological mechanisms of lung fibrosis, one of the therapeutic approaches considered was the use of a non-toxic anti-ulcer drug geranylgeranylacetone (GGA), which induces the expression of intracellular chaperone heat shock protein 70. The plausibility of this approach was shown by the group of Kim and colleagues in a study where they treated mice with GGA before and after irradiation and found out that after 6 months the animals had less pronounced lung fibrosis and had less signs of EMT in lung tissue compared with the placebo group (107). However, one possible drawback in using this drug in clinical practice is that it can also reduce the efficacy of irradiation as an anti-tumor treatment (108).

Influence on DDHA-ADMA-iNOS-NO Axis
The second possible therapeutic approach is based on the rationale that activated iNOS in the development of lung fibrosis is the source of excess of nitric oxide, which causes secondary injury to the lung. Studies in mice showed that at least in the bleomycin model the use of iNOS inhibitors resulted in significant reduction in the degree of lung fibrosis compared to animals from the placebo groups (81, 83). Pullamsetti and colleagues demonstrated a protective role of a selective DDHA inhibitor L-291 in the development of bleomycin-induced lung fibrosis. Interestingly, the inhibitor seemed to affect both ADMA-independent (antifibrotic) and ADMA-dependent (antiproliferative) pathways of lung fibrosis development (83).

Reducing TGF-β1-Mediated Effects
According to the current state of knowledge, TGF-β1 plays a key role in the development of lung fibrosis (108). Therefore, many efforts are concentrated on different ways to interfere with the pathways triggered by TGF-β1 activity. One possibility would be to block signal transduction mediated by TGF-β1 and the feasibility of this approach was demonstrated in rodents where the use of small molecules inhibiting TGF-β1 receptors resulted in decreased severity of lung fibrosis induced by irradiation (26, 109). Another approach to limit the activity of TGF-β1 is to use specific small interfering RNA (siRNA). In a study performed by Lu and co-workers it was demonstrated that in a mouse model the use of TGF-β1-siRNA significantly attenuated the increase in TGF-β1 serum levels after the entire thorax irradiation and that the treatment improved histological signs of inflammation and lung oedema (110). Another possibility considered is the use of a replication-defective adenoviral vector (AdTβ1-ExR) that increases the levels of soluble TGF-β type II receptor (111). This approach has been tested in irradiated rats where it was shown that the adenoviral vector reduced TGF-β expression, myofibroblast proliferation, and macrophage infiltration in the lungs (111). Interestingly, there is already a drug – ambroxol – which affects TGF-β1 production. Clinical studies showed that oral treatment with ambroxol from the beginning of radiotherapy significantly attenuated the rise of TGF-β1 concentration in the blood, protected patients from declining lung diffusion capacity, and reduced the incidence of pneumonitis and lung fibrosis (111).

Another therapeutic option and promising approach is the application of pirfenidone, an oral synthetic molecule with antifibrotic, antioxidant and anti-inflammatory effects. Pirfenidone inhibits TGF-β1 (112) and has been successfully used in clinical studies (14, 113–115). Recently the use of this drug in a murine model of radiation-induced pulmonary fibrosis revealed an extended median survival time and decreased accumulation of collagen and fibrosis in lung tissues. Pirfenidone also reduced TGF-β1 levels and phosphorylation of Smad3 under experimental conditions (12). Further, pirfenidone has been efficiently used in combination with sunitinib and radiotherapy in Lewis lung carcinoma (116).

Regulation of Immune Response
One of main component in the development of lung fibrosis is the disbalance of the immune system. It can be speculated that a shift in the immune response from a pro-fibrotic pathway could attenuate and/or prevent lung fibrosis. There is a promising drug, cytosine-phosphate-guanine oligodeoxyribonucleotides (CpG-ODNs), which stimulates the production of pro-inflammatory cytokines and demonstrated a protective effect on post-radiation lung fibrosis development in a mouse model (117, 118). The attenuation of lung fibrosis was associated with reduction of serum concentrations of TGF-β1 and lower amount of hydroxyproline in the lung tissue (117, 118).

Preventing Alveolar Epithelial Injury
Earlier studies on the role of the alveolar epithelium in the pathogenesis of radiation-induced fibrosis concluded that the development of pneumonitis and pulmonary fibrosis is caused by the disruption of the balance between various cell populations of the pulmonary parenchyma (119). The myofibroblasts of the alveolar wall were formerly expected as the most active cell during fibrogenesis; however, AET I cells, endothelial cells, and the alveolar macrophages are the primary target of injury (108). Subsequently, products of all these cells, particularly of AET I cells, and signals from disturbed intercellular epithelial adhesion and other factors stimulate the AET II cells to proliferate faster, and to secrete many cytokines in autocrine and paracrine mode (119). This results in accelerated proliferation and differentiation of AET II cells into AET I cells (120). This presumably impaired transdifferentiation process includes an increased presence of an intermediate cell type that is cuboidal or flat and expresses both AET I and AET II cell markers (121). The underlying mechanisms which include apoptosis and senescence of alveolar epithelial cells are poorly understood. AET I cells seem to die rather by necrosis than by apoptosis as shown in ultrastructural studies (122, 123). Knockout of AET I-specific proteins (for example PAI-1, Cav-1, RAGE, P2X7R, ICAM-1) in mice show signs of resistance to lung injury and fibrosis (80, 124–127), thus indicating the importance and involvement of the alveolar epithelial cells, namely the AET I cells in fibrogenesis. Preventing alveolar epithelial injury implicates the maintenance of alveolar barrier function e.g., to stabilize...
epithelial tightness by proper tight junctions as predominant structures between alveolar epithelial cells (128). Disruption of TJs with subsequent loss of alveolar epithelial integrity plays an important role in the development of pulmonary fibrosis (129). Despite the alveolar epithelial barrier function being more resistant to radiation than that of the pulmonary capillary endothelium, intact alveolar epithelial permeability is of critical importance in keeping the alveolar space relatively free of fluid during acute radiation-induced lung injury (130). Promising tools for restoration of alveolar epithelial barrier function in radiation-induced pulmonary fibrosis, however, are missing.

New Techniques of Radiotherapy

Radiotherapy techniques have changed significantly over the past few decades due to improvements in engineering and computing. The use of state-of-the-art equipment employing the recent advances in radiation oncology has a huge potential to limit the risk of radiation induced pulmonary damage. By the end of the 90s, 3-dimensional conformal radiotherapy (3DCRT) was developed, where 3D imaging data is used before the irradiation to design a minimum number of radiation beams with a predefined fixed shape and uniform dose distribution matching the shape of the tumor mass (131). Later this approach was improved into IMRT (intensity-modulated radiotherapy), which allows variation of dose within each beam and typically uses more beams than 3DCRT which leads to more conformal dose distribution (132). This technique was made possible by the use of computer-controlled multi-leaf collimators and advanced treatment planning algorithms that are capable of creating the desired dose variation inside the radiation field (133). In the past decade this approach was further developed into techniques like VMAT (volumetric modulated arc therapy) where the irradiation is carried out while rotating the irradiator around the patient and the radiation dose is accurately shaped to the tumor while minimizing the dose received by the surrounding tissues (134). Further advances include the stereotactic body radiotherapy (SBRT), where immobilization devices and improved real-time imaging have allowed clinicians to administer high ablative doses to precisely target the tumor. The effectiveness of SBRT arises from the cumulative biologically effective dose that can be achieved while maintaining a sharp dose gradient fall off outside the target, preventing dose to critical structures (135). However, this technique is not free of side effects, including airway toxicity and consequent atelectasis, stenosis/stricture, airway necrosis and/or fistula formation (more prominent in patients with centrally located tumors) (136–138), spontaneous pneumothorax (139, 140), pneumonitis (141), chest wall pain and rib fracture (142, 143). Parallel to the development of these photon-based irradiation techniques, research is also focused on particle therapy, which is based on the use of protons and carbon ions to further reduce the radiation dose received by the healthy tissue. In contrast to photons, particle therapy aims to achieve proper radiation dose concentrated predominantly at a precise depth, which allows additional protection to the normal tissue (144, 145).

CONCLUSION

Post-radiation lung fibrosis is a common and currently untreatable adverse event of radiation therapy. To date, much is known about the pathophysiologival processes of the development of lung fibrosis and pathways supporting the spread of pathological processes in the lungs. This knowledge led to recognition of the key points of fibrotic reaction and hopefully in the future will result in a development of highly effective therapeutic approaches which could be used to improve the duration and quality of life of patients after radiotherapy while at the same time will not limit the effectiveness of the applied anti-neoplastic therapy.

AUTHOR CONTRIBUTIONS

NJ, EK, AM, MK, RR, and PS: drafted the manuscript and approved the final version.

FUNDING

This review was supported by the Partnership Program Technische Universität Dresden – Saint Petersburg State University. Open Access Funding by the Publication Fund of the TU Dresden.

REFERENCES

1. eviCore Radiation Therapy Clinical Guidelines. Available online at: https://www.evicore.com/ReferenceGuidelines/eviCore%20Radiation%20Therapy%20Criteria_V1.2.0.18_Eff04.01.2018.pdf (accessed April 1, 2018).
2. Tyldesley S, Delaney G, Foroudi F, Barbera L, Kerba M, Mackillop W. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys. (2011) 79:1507–15. doi: 10.1016/j.ijrobp.2009.12.070
3. Chen MJ, Novaes PE, Gadia R, Motta R. Guidelines for the treatment of lung cancer using radiotherapy. Rev Assoc Med Bras. (2017) 63:729–32. doi: 10.1590/1806-9282.63.09.729
4. Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, et al. Guidelines on the radical management of patients with lung cancer. Thorax. (2010) 65(Suppl. 3):iii1–27. doi: 10.1136/thx.2010.145938
5. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. (2010) 76:S70–6. doi: 10.1016/j.ijrobp.2009.06.091
6. Morgan GW, Brett SN. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys. (1995) 31:361–9. doi: 10.1016/0360-3016(94)00477-3
7. Makimoto T, Tsuchiya S, Hayakawa K, Saitoh R, Mori M. Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol. (1999) 29:192–7. doi: 10.1093/jjco/29.4.192
8. Weytjens R, Erven, K, De Ruyscher D. Radiation pneumonitis: occurrence, prediction, prevention and treatment. Belg J Med Oncol. (2013) 7:105–110.
9. Williams JP, Johnston CJ, Finkelstein JN. Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?
25. Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and.

24. Urbanic JJ, Lally B, Blackstock AW. The best-laid plans . . . often go awry . . . .

14. Simone NL, Soule BP, Gerber L, Augustine E, Smith S, Altemus.

19. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al.

16. Emami B. Tolerance of normal tissue to therapeutic radiation. Rep Radiother.

27. Zhao L, Sheldon K, Chen M, Yin MS, Hayman JA, Kalemkerian.

26. Anscher MS, Thrasher B, Zgonjanin L, Rabbani ZN, Corbley MJ, Fu K, et al.

13. De Ruysscher D, Granton PV, Lieuwes NG, van Hoof S, Wollin L, Wynand.

10. Medhora M, Gao F, Jacobs ER, Moulder JE. Radiation damage to the lung:

18. Wirsdorfer F, Jendrossek V. Modeling DNA damage-induced pneumopathy.

17. Giridhar P, Mallick S, Rath GK, Julka PK. Radiation induced lung injury:

28. Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T, Rubin P, Interleukin

30. Sasaki R, Soejima T, Matsumoto A, Maruta T, Yamada K, Ota Y, et al. Clinical

32. Turkkan G, Willems Y, Hendriks LEL, Mostard R, Cenomans L, Gietema

34. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, et al. Impact of
definitive radiotherapy in patients with non-small cell lung cancer.

35. De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Pechoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. (2017) 124:1–10. doi: 10.1016/j.radonc.2017.06.003

36. Yoshitake T, Shioyama Y, Asai K, Nakamura K, Sasaki T, Ohga S, et al. Impact of interstitial changes on radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Anticancer Res. (2015) 35:4909–13. doi: 10.21873/anticanres.11173

37. Chen H, Senan S, Nosset EJ, Boldt RG, Warner A, Palma DA, et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys. (2017) 98:622–31. doi: 10.1016/j.ijrobp.2017.03.010

38. Harada H, Murayama S. Proton beam therapy in non-small cell lung cancer: state of the art. Lung Cancer (Austin). (2017) 8:141–5. doi: 10.1016/l.ctt.2017.05.004

39. Ono T, Hayreyma M, Nakamura T, Kimura K, Hayashi Y, Azami Y, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. Radiat Oncol. (2016) 11:56. doi: 10.1186/s13014-016-0637-3

40. Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. (2013) 82:260–5. doi: 10.1016/j.lungcan.2013.08.024

41. Kim H, Pyo H, Noh JM, Lee W, Park B, Park HY, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. (2019) 14:19. doi: 10.1186/s13014-019-1221-4

42. Chaudhary NJ, Roth GH, Hilberg E, Muller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF,VEGF and FGf signalling attenuates fibrosis. Eur Respir J. (2007) 29:976–85. doi: 10.1183/09031936.00152106

43. Inomata M, Nishioya Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. (2015) 10:89–98. doi: 10.2147/CE.S82905

44. Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. (2020) 20:3. doi: 10.1186/s12890-019-1030-4

45. Chu KA, Yee CC, Kuo FH, Lin WR, Hsu CW, Chen TH, et al. Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton's jelly. Stem Cell Res Ther. (2020) 11:513. doi: 10.1186/s13287-020-00212-y
46. Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancer-associated fibroblasts within the tumor microenvironment. *Adv Drug Deliv Rev* (2016) 99:186–96. doi: 10.1016/j.addr.2015.07.007

47. Kalluri R. The biology and function of fibroblasts in cancer. *Nat Rev Cancer* (2016) 16:582–98. doi: 10.1038/nrc.2016.73

48. Barbazan I, Matic Vignjevic D. Cancer associated fibroblasts: is the force the path to the dark side? *Curr Opin Cell Biol.* (2019) 56:71–9. doi: 10.1016/j.ceb.2018.09.002

49. Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, et al. Radiotherapy induces stromal fibroblast activation and promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cells through tumor-stromal interactions. *Cancer Res.* (2004) 64:3215–22. doi: 10.1158/0008-5472.CAN-03-1577

50. Li D, Qu C, Ning Z, Wang H, Zang K, Zhuang L, et al. Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. *Am J Cancer Res.* (2016) 6:2192–206.

51. Renschler MF. The emerging role of reactive oxygen species in cancer. *Eur J Cancer.* (2004) 40:1934–40. doi: 10.1016/j.ejca.2004.02.031

52. Jeong H, Bok S, Hong BJ, Choi HS, Ahn GO. Radiation-induced immune responses: mechanisms and therapeutic perspectives. *Blood Res.* (2016) 51:157–63. doi: 10.5045/br.2016.51.3.157

53. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. *Cancer Res.* (2004) 64:3215–22. doi: 10.1158/0008-5472.CAN-03-2464

54. Li X, Qian L, Li Z, Fan EK, Li Y, Wu L, et al. TLR4-Upregulated IL-1beta and IL-1RI promote alveolar macrophage pyroptosis and lung inflammation through an autocrine mechanism. *Sci Rep.* (2016) 6:31663. doi: 10.1038/srep31663

55. Sohn SH, Lee JM, Park S, Yoo H, Kang JW, Shin D, et al. The inflammation accelerates radiation-induced lung inflammation and fibrosis in mice. *Environ Toxicol Pharmacol.* (2015) 39:917–26. doi: 10.1016/j.etap.2015.02.019

56. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death. *Cell Death Differ.* (2012) 19:107–20. doi: 10.1038/cdd.2011.96

57. Genovese T, Cuzzocrea S, Di Paola R, Failla M, Mazzon E, Sortino MA, et al. Inhibition or knock out of inducible nitric oxide synthase result in the cryopyrin inflammasome independent of Toll-like receptor signaling. *Immunity.* (2007) 26:433–43. doi: 10.1016/j.immuni.2007.03.008

58. Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Koningshoff RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in the cryopyrin inflammasome independent of Toll-like receptor signaling. *J Immunol.* (2013) 189:381–91. doi: 10.5017/jimmunol.2012.118:109217. doi: 10.1016/j.biopha.2019.109217

59. Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. *Blood Res.* (2010) 77:1198–205.

60. Liang J, Zhang Y, Xie T, Liu N, Chen H, Geng Y, et al. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and inflammation in response to ionizing radiation. *Int J Radiat Oncol Biol Phys.* (2016) 93:205–16. doi: 10.1016/j.ijrobp.2016.03.028

61. Kasper M, Traub O, Reimann T, Bjermer L, Grossmann H, Muller M, et al. The role of dimethylarginine dimethylaminohydrolase (DDAH) in the cryopyrin inflammasome independent of Toll-like receptor signaling. *Sci Transl Med.* (2016) 8:341ra53. doi: 10.1126/scitranslmed.3001725

62. Pharmacological manipulation of the NLRP3 inflammasome accelerates radiation-induced lung inflammation and fibrosis. *Am J Respir Cell Mol Biol.* (2013) 49:226–37. doi: 10.1165/rcmb.2012-0133OC

63. Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced G protein-coupled receptor-mediated calcium fluxes. *J Biol Chem.* (2006) 281:21212–22. doi: 10.1074/jbc.M602219200

64. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. *Am J Respir Crit Care Med.* (2014) 189:784–93. doi: 10.1164/rccm.201310-1825OC

65. Kabaj S, Cuzzocrea S, Di Paola R, Failla M, Mazzon E, Sortino MA, et al. Inhibition or knock out of inducible nitric oxide synthase result in the cryopyrin inflammasome independent of Toll-like receptor signaling. *Am J Respir Crit Care Med.* (2014) 189:784–93. doi: 10.1164/rccm.201310-1825OC

66. Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Koningshoff RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in the cryopyrin inflammasome independent of Toll-like receptor signaling. *J Immunol.* (2013) 189:381–91. doi: 10.5017/jimmunol.2012.118:109217. doi: 10.1016/j.biopha.2019.109217

67. Hirota JA, Knight DA. Human airway epithelial cell innate immunity: relevance to asthma. *Curr Opin Immunol.* (2012) 24:746–70. doi: 10.1016/j.coi.2012.08.012

68. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. *Cell Mol Immunol.* (2016) 13:158–69. doi: 10.1016/j.cmi.2015.09.001

69. Wei J, Wang H, Wang H, Wang Y, Meng L, Xin Y, et al. The role of NLRP3 inflammasome activation in radiation damage. *Biomed Pharmacother.* (2019) 118:109217. doi: 10.1016/j.biopha.2019.109217

70. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation. *Int J Mol Sci.* (2020) 21:3238. doi: 10.3390/ijms20133328

71. Abderrazak A, Syroverts T, Couchie D, El Hadri K, Friguet B, Simmet T, et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. *Redox Biol.* (2015) 4:296–307. doi: 10.1016/j.redox.2015.01.008

72. He X, Qian Y, Li Z, Fan EK, Li Y, Wu L, et al. TLR4-Upregulated IL-1beta and IL-1RI promote alveolar macrophage pyroptosis and lung inflammation through an autocrine mechanism. *Mol Syst Biol.* (2014) 10:e0115447.
86. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. *Nat Struct Biol.* (2001) 8:679–83. doi: 10.1038/90387

87. Cooke JP, GhebreMariam YT. DDAH says NO to ADMA. *Proc Natl Acad Sci U S A.* (2006) 103:13180–5. doi: 10.1073/pnas.0605669103

88. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Reduction in fibrotic tissue formation in mice genetically deficient of pulmonary fibrosis. *Am J Pathol.* (2003) 163:445–52.

89. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. *Am J Pathol.* (2015) 186:15407–8. doi: 10.1016/j.ajpath.2015.02.004

90. Choi SH, Hong ZY, Nam JK, Lee HJ, Jang J, Yoo RJ, et al. A hypoxia-induced vascular endothelial-to-mesenchymal transition in development of radiation-induced pulmonary fibrosis. *Cancer Clin Res.* (2015) 21:3716–26. doi: 10.1158/1078-0432.CCR-14-13193

91. Almeida C, Nagarajan D, Tian J, Leal SW, Wheeler K, Munley M, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. *Proc Natl Acad Sci U S A.* (2006) 103:13180–5. doi: 10.1073/pnas.0605669103

92. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase. *Circ Res.* (2003) 92:226–33. doi: 10.1161/01.RES.0000052990.68216.EF

93. Cooke JP, Ghebremariam YT. DDAH says NO to ADMA. *Proc Natl Acad Sci U S A.* (2006) 103:13180–5. doi: 10.1073/pnas.0605669103

94. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Reduction in fibrotic tissue formation in mice genetically deficient of pulmonary fibrosis. *Am J Pathol.* (2003) 163:445–52.

95. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. *Am J Pathol.* (2015) 186:15407–8. doi: 10.1016/j.ajpath.2015.02.004

96. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. *Chest.* (2019) 156:150–62. doi: 10.1016/j.chest.2019.03.033

97. Kim JS, Son Y, Jung MG, Jeong YL, Kim SH, Lee SJ, et al. Geranylgeranylatedcine alleviates radiation-induced lung injury by inhibiting epithelial-to-mesenchymal transition signaling. *Mol Med Rep.* (2016) 13:4666–70. doi: 10.3892/mmr.2016.5121

98. Bartholomew JR. Update on the management of venous thromboembolism. *Cleve Clin J Med.* (2017) 84:39–46. doi: 10.3949/ccjm.84.s.3.04

99. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. *J Pathol.* (2014) 234:352–64. doi: 10.1002/path.4534

100. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. *Am J Pathol.* (2012) 180:1340–55. doi: 10.1016/j.ajpath.2012.02.004
125. Shivshankar P, Brampton C, Miyasato S, Kasper M, Thannickal VJ, Le Saux CJ. Caveolin-1 deficiency protects from pulmonary fibrosis by modulating epithelial cell senescence in mice. *Am J Respir Cell Mol Biol*. (2012) 47:28–36. doi: 10.1165/rcmb.2011-0394OC.

126. Engert JM, Kliment CR, Ramsgaard L, Milutinovic PS, Crum L, Tobolowski JM, et al. Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. *Int J Clin Exp Pathol*. (2011) 4:241–4.

127. Hamaguchi Y, Nishizawa Y, Yasui M, Hasegawa M, Kaburagi Y, Komura K, et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. *Am J Pathol*. (2002) 161:1607–18. doi: 10.1016/S0002-9440(10)64439-2.

128. Wittekindt OH. Tight junctions in pulmonary epithelia during lung inflammation. *Pflugers Arch*. (2017) 469:135–47. doi: 10.1007/s00424-016-1917-3.

129. Kulkarni T, de Andrade J, Zhou Y, Luckhardt T, Thannickal VJ. Alveolar epithelial disintegrity in pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol*. (2016) 311:L185–91. doi: 10.1152/ajplung.00115.2016.

130. Suzuki S, Noda M, Akaizawa T, Song C, Tsubochi H, Suzuki T, et al. Intact alveolar epithelial permeability and transalveolar fluid absorption after thoracic irradiation in rats. *Radiat Res*. (1999) 152:517–22. doi: 10.2307/3580148.

131. Barazzuol L, Coppes RP, van Luijk P. Prevention and treatment of radiotherapy-induced side effects. *Mol Oncol*. (2020) 14:1538–54. doi: 10.1007/s00424-016-1917-3.

132. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve JM, et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. *Am J Pathol*. (2002) 161:1607–18. doi: 10.1016/S0002-9440(10)64439-2.

133. Garibaldi C, Jereczek-Fossa BA, Marvaso G, Dicuonzo S, Rojas JD, Yoshitake T, et al. Spontaneous pneumothorax after stereotactic radiotherapy for non-small-cell lung cancer. *Ipyn J Radiol*. (2009) 27:269–74. doi: 10.1007/s11604-009-0333-4.

134. Nicosia L, Sicignano G, Rigo M, Figlia V, Cuccia F, De Simon et al. Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. *Int J Radiat Oncol Biol Phys*. (2011) 6:140. doi: 10.3389/fonc.2016.00140.

135. Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. *Radiat Oncol*. (2014) 9:210. doi: 10.1186/1748-717X-9-210.

136. Karlsson K, Nyman J, Baumann P, Wersall P, Druge N, Gagliardi G, et al. Retrospective cohort study of bronchial dose-volume and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. *Int J Radiat Oncol Biol Phys*. (2013) 87:590–5. doi: 10.1016/j.ijrobp.2013.06.2055.

137. Speiser BL, Spratling L. Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. *Int J Radiat Oncol Biol Phys*. (1993) 25:589–97. doi: 10.1016/0360-3016(93)90003-E.

138. Kang KH, Okoye CC, Patel RB, Siva S, Biswas T, Ellis RI, et al. Complications from stereotactic body radiotherapy for lung cancer. *Cancers (Basel)*. (2015) 7:981–1004. doi: 10.3390/cancers7020820.

139. Ohnishi K, Shioyama Y, Nomoto S, Sasaki T, Ohga S, Yoshitake T, et al. Spontaneous pneumothorax after stereotactic radiotherapy for non-small-cell lung cancer. *Ipyn J Radiol*. (2009) 27:269–74. doi: 10.1007/s11604-009-0333-4.

140. Seppenwoole Y, De Jaeger K, Boersma LJ, Belderbos JS, L&esque JV. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. (2004) 60:748–54. doi: 10.1016/j.ijrobp.2004.03.037.

141. Macfadyen RJ, Lees KR, Reid JL. Perindopril. A review of its pharmacokinetics and clinical pharmacology. *Drugs*. (1990) 39(Suppl. 1):49–63. doi: 10.2165/00003495-199000391-00009.

142. Andolino DL, Forquer JA, Henderson MA, Barriger RB, Shapiro RH, Brabham JG, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. *Int J Radiat Oncol Biol Phys*. (2011) 80:692–7. doi: 10.1016/j.ijrobp.2010.03.020.

143. Voroney JP, Hope A, Dahele MR, Purdie TG, Franks KN, Pearson S, et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. *J Thorac Oncol*. (2009) 4:1035–7. doi: 10.1097/JTO.0b013e3181ae2962.

144. Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. *Nat Rev Clin Oncol*. (2017) 14:483–95. doi: 10.1038/nrclinonc.2017.30.

145. Ebner DK, Kamada T. The emerging role of carbon-ion radiotherapy. *Front Oncol*. (2016) 6:140. doi: 10.3389/fonc.2016.00140.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Jarzebska, Karetinukova, Markov, Kasper, Rodionov and Spith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.